Amyloid from antibody fragments around blood vessels impairs liver regeneration after surgery in old mice; the antibody anselamimab reduced deposits and improved regeneration
Amyloid from antibody fragments around blood vessels impairs liver regeneration after surgery in old mice; the antibody anselamimab reduced deposits and improved regeneration
On November 4, Cell Reports published a study by a group at Nanchang University. After 70% of the liver was removed, 22-month-old mice showed poorer liver regeneration than two-month-old mice. Amyloid deposits surrounded their blood vessels, consisting of fibers formed from aggregated antibody light chains.
The liver's ability to regenerate after partial removal declines with age: according to data from Korean surgeons, the remaining liver in right-lobe donors aged 55 and older regenerated to an average of 87,9% of its original volume over six months, compared with 95,8% in donors younger than 30. One reason lies in the liver cells themselves: during chronic injury, the proteins YAP and TAZ help cells activate Igf2, a gene that provides a signal for cell division, and this response is impaired in old mice. Another is limited blood vessel growth: old mice have fewer vessels after surgery.
In old mice, the cells lining blood vessels had increased levels of PSMB8, a component of the immunoproteasome, which is activated during inflammation and breaks down proteins tagged for degradation. Mice lacking PSMB8 specifically in these cells showed better liver regeneration. Blocking the immunoproteasome with PR-957 in cultured cells caused degradation tags to accumulate on proteins it normally breaks down. These included TAZ, which activates genes involved in blood vessel growth. PR-957 helped the cells form vessel-like tubes, but this effect was lost when TAZ was suppressed. TAZ protein levels were lower in the aged liver, particularly around blood vessels. Removing PSMB8 restored TAZ levels, and a substance that increased TAZ improved regeneration.
Interferons, which signal inflammation, usually activate PSMB8, but RNA analysis of the aged liver showed a different pattern. “Unexpectedly, known activators, such as interferons, were barely detectable,” the authors write. Instead, genes encoding proteins prone to forming amyloid, including light chains and serum amyloid A, were more active. In cultured cells, serum amyloid A activated PSMB8, but removing its genes in old mice did not change liver regeneration.
Congo red staining revealed amyloid along the blood vessel walls in the aged liver, and protein analysis identified light-chain polymers. Single-cell RNA sequencing identified plasma-like cells there (immune cells that produce antibodies), and staining showed these cells beside the deposits. The authors suggest that the light chains are produced locally, reasoning that leakage from the blood would have produced uniform staining throughout the tissue. Fibers assembled in vitro from fragments of human light chains increased PSMB8 and reduced TAZ in human and mouse vascular cells.
The authors consider complete immunoproteasome blockade risky because the immunoproteasome prevents proteins from forming toxic aggregates. They hypothesized that clearing amyloid would reduce immunoproteasome activation and improve regeneration, and tested this with anselamimab, an antibody that targets the deposits themselves. Anselamimab reduced deposits in old mice: PSMB8 levels fell, TAZ levels recovered, blood vessels became more abundant, and liver regeneration improved. Young mice transfused with blood from old mice showed poorer liver regeneration, more light chains, and fewer blood vessels; anselamimab reversed these changes.
Anselamimab was developed to treat AL amyloidosis, in which light chains are deposited mainly in the heart and kidneys. In two phase three trials (the CARES program, 406 patients), AstraZeneca reported that the primary endpoint (mortality and cardiovascular hospitalizations) was not met in the overall population. In a prespecified subgroup of 72 patients with kappa light chains, 31,3% of those receiving anselamimab died, compared with 58,3% of those receiving placebo.